fashion -WSS

fashion

author：knowledge 2025-09-27 10:01:55 - browse：42263

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： New chart reveals military’s vast involvement in Operation Warp Speed

WSS

Assistant physicians can help address the primary care shortage

Hey, doctors: Don't be no

Biden White House, tech companies launch new safeguards around emerging AI technology

Eli Lilly CEO gives to Mike Pence presidential super PAC

Grad students accuse University of California of wage theft

Assistant physicians can help address the primary care shortage

hotspot

fashion

explore

Anesthesiologist group: stop taking Ozempic before surgery

It's time to take a new tack for treating Alzheimer's

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The unintended consequences of overturning Roe v. Wade

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

New chief aims to remake Sanofi Genzyme

Heart attack and stroke risk calculators need revising

A new deal aims to ramp up use of AI in rehab care decisions

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

hotspot

Pfizer's RSV vaccine recommended for approval in Europe

FDA weighs limits of animal data in assessing artificial wombs

Free Covid tests will again be offered to all U.S. households

The unintended consequences of overturning Roe v. Wade

'A game

It's time to take a new tack for treating Alzheimer's

hotspot

entertainment

focus

focus